Altamira Therapeutics Ltd.

NASDAQ (USD): Altamira Therapeutics Ltd. (CYTO)

Last Price


Today's Change

-0.08 (6.40%)

Day's Change

1.15 - 1.28

Trading Volume



Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare


CEO:  Dr. Thomas Meyer Ph.D. Dr. Thomas Meyer Ph.D.

Full Time Employees:  10 10

IPO Date:  2014-08-06 2014-08-06

CIK:  0001601936 0001601936

ISIN:  BMG0360L1349 BMG0360L1349

CUSIP:  G0360L100 G0360L100

Beta:  2.43 2.43

Last Dividend:  0.00 0.00

Dcf Diff:  -0.03 -0.03

Dcf:  1.19 1.19


Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.


Clarendon House,
Hamilton, HM 11, BM

441 295 5950

Be the first to like this. Showing 0 of 0 comments

Post a Comment